La estimulación cardiaca es un procedimiento terapéutico ampliamente conocido. En la actualidad su utilización óptima depende fundamentalmente de la valoración individualizada de la afección del paciente que precisa un marcapasos y de conocer las múltiples posibilidades de los dispositivos disponibles en el mercado. Existen algunas situaciones especiales que, por su relevancia clínica y las dudas que pueden generar en cuanto a estimulación, merece la pena tratar de forma individualizada. En este trabajo se exponen los conocimientos actuales en cinco de esas situaciones.
Palabras clave
Marcapasos
Arritmia
Síncope
Apnea del sueño
Miocardiopatía hipertrófica
Enfermedades neuromusculares
Desfibrilador
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
A.C. Skanes, A.D. Krahn, R. Yee, G.J. Klein, S.J. Connolly, C.R. Kerr, et al.
Canadian Trial of Physiologic Pacing. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators.
J Am Coll Cardiol, (2001), 38 pp. 167-172
[2.]
R. Ricci, C. Pignalberi, L. Santini, B. Magris, M. Russo, N. Grovale, et al.
Physiologic pacing for atrial fibrillation prevention in sinus node disease: long-term results.
Pacing Clin Electrophysiol, (2006), 29 pp. S54-S60
[3.]
A.B. Hesselson, V. Parsonnet, A.D. Bernstein, G.J. Bonavita.
Deleterious effects of long-term single-chamber ventricular pacing in patients with sick sinus syndrome: the hidden benefits of dualchamber pacing.
J Am Coll Cardiol, (1992), 19 pp. 1542-1549
[4.]
K. Stangl, K. Seitz, A. Wirtzfeld, E. Alt, H. Blomer.
Differences between atrial single chamber pacing (AAI) and ventricular single chamber pacing (VVI) with respect to prognosis and antiarrhythmic effect in patients with sick sinus syndrome.
Pacing Clin Electrophysiol, (1990), 13 pp. 2080-2085
[5.]
E.B. Sgarbossa, S.L. Pinski, J.D. Maloney, T.W. Simmons, B.L. Wilkoff, L.W. Castle, et al.
Chronic atrial fibrillation and stroke in paced patients with sick sinus syndrome: relevance of clinical characteristics and pacing modalities.
Circulation, (1993), 88 pp. 1045-1053
[6.]
F. Hofgartner, B. Maier, R. Eisele, J. Hauber, H. Sigel, Pacemaker therapy for the sick sinus node syndrome.
Does the atrially involved pacemaker system lower the frequency of atrial fibrillation and thromboembolic complications as well as mortality?.
Dtsch Med Wochenschr, (1994), 119 pp. 1683-1689
[7.]
H.R. Andersen, J.C. Nielsen, P.E. Thomsen, L. Thuesen, P.T. Mortensen, T. Vesterlund, et al.
Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome.
Lancet, (1997), 350 pp. 1210-1216
[8.]
S.J. Connolly, C.R. Kerr, M. Gent, R.S. Roberts, S. Yusuf, A.M. Gillis, et al.
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators.
N Engl J Med, (2000), 342 pp. 1385-1391
[9.]
G.A. Lamas, K.L. Lee, M.O. Sweeney, R. Silverman, A. Leon, R. Yee, N.A. Estes 3rd, A. Greenspon, L. Goldman, et al.
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction.
N Engl J Med, (2002), 346 pp. 1854-1862
[10.]
G.A. Lamas, E.J. Orav, B.S. Stambler, K.A. Ellenbogen, E.B. Sgarbossa, S.K. Huang, et al.
Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators.
N Engl J Med, (1998), 338 pp. 1097-1104
[11.]
M.O. Sweeney, A.S. Hellkamp, K.A. Ellenbogen, A.J. Greenspon, R.A. Freedman, K.L. Lee, MOde Selection Trial Investigators, et al.
Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction.
Circulation, (2003), 107 pp. 2932-2937
[12.]
J.C. Nielsen, L. Kristensen, H.R. Andersen, P.T. Mortensen, O.L. Pedersen, A.K. Pedersen.
A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome.
J Am Coll Cardiol, (2003), 42 pp. 614-623
[13.]
G. Milasinovic, J. Sperzel, T.W. Smith, H. Mead, J. Brandt, W.K. Haisty, Worldwide EnPulse Investigators, et al.
Reduction of RV pacing by continuous optimization of the AV interval.
Pacing Clin Electrophysiol, (2006), 29 pp. 406-412
[14.]
A.M. Gillis, H. Purerfellner, C.W. Israel, H. Sunthorn, S. Kacet, M. Anelli-Monti, Medtronic Enrhythm Clinical Study Investigators, et al.
Reducing unnecessary right ventricular pacing with the managed ventricular pacing mode in patients with sinus node disease and AV block.
Pacing Clin Electrophysiol, (2006), 29 pp. 697-705
[15.]
A. Savoure, G. Frohlig, D. Galley, P. Defaye, S. Reuter, P. Mabo, et al.
A new dual-chamber pacing mode to minimize ventricular pacing.
Pacing Clin Electrophysiol, (2005), 1 pp. S43-S46
[16.]
M.O. Sweeney, K.A. Ellenbogen, D. Casavant, R. Betzold, T. Sheldon, F. Tang, The Marquis MVP Download Investigators, et al.
Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs.
J Cardiovasc Electrophysiol, (2005), 16 pp. 811-817
[17.]
R. Ricci, M. Santini, L. Padeletti, G. Boriani, A. Capucci, G. Botto, et al.
Atrial tachyarrhythmia recurrence temporal patterns in bradycardia patients implanted with antitachycardia pacemakers.
J Cardiovasc Electrophysiol, (2004), 15 pp. 44-51
[18.]
E. Hoffmann, N. Sulke, N. Edvardsson, J. Ruiter, T. Lewalter, A. Capucci, Atrial Fibrillation Therapy Trial Investigators, et al.
New insights into the initiation of atrial fibrillation: a detailed intraindividual and interindividual analysis of the spontaneous onset of atrial fibrillation using new diagnostic pacemaker features.
Circulation, (2006), 113 pp. 1933-1941
[19.]
I. Carlson, J. Messenger, S. Beau, S. Kalbfleisch, P. Gervais, D.A. Cameron, et al.
A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT).
J Am Coll Cardiol, (2003), 42 pp. 627-633
[20.]
I.F. Lozano, A. Vincent, J. Roda, M. Mendez, J.M. Ferrer, F. Andrade, et al.
Paroxysmal atrial fibrillation prevention by pacing in patients with pacemaker indication.
Europace, (2003), 5 pp. 267-273
[21.]
T. Lewalter, A. Yang, D. Pfeiffer, J. Ruiter, G. Schnitzler, T. Markert, et al.
Individualized selection of pacing algorithms for the prevention of recurrent atrial fibrillation: Results from the VIP registry.
Pacing Clin Electrophysiol, (2006), 29 pp. 124-134
[22.]
M.R. Gold, E. Hoffmann, SAFARI Investigators.
Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI).
Am Heart J, (2006), 152 pp. 231-236
[23.]
A. Bayes de Luna, M. Cladellas, R. Oter, P. Torner, J. Guindo, V. Marti, et al.
Interatrial conduction block and retrograde activation of the left atrium and paroxysmal supraventricular tachy arrhythmia.
Eur Heart J, (1988), 9 pp. 1112-1118
[24.]
S. Saksena, A. Prakash, P. Ziegler, J.D. Hummel, P. Friedman, V.J. Plumb, DAPPAF Investigators, et al.
Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy.
J Am Coll Cardiol, (2002), 40 pp. 1140-1150
[25.]
L. Padeletti, H. Purerfellner, S.W. Adler, T.J. Waller, M. Harvey, L. Horvitz, Worldwide ASPECT Investigators, et al.
Combined efficacy of atrial septal lead placement and atrial pacing algorithms for prevention of paroxysmal atrial tachyarrhythmia.
J Cardiovasc Electrophysiol, (2003), 14 pp. 1189-1195
[26.]
S.J. Bailin, S. Adler, M. Giudici.
Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: results of a multicenter randomized trial.
J Cardiovasc Electrophysiol, (2001), 12 pp. 912-917
[27.]
R. Mosqueda-García, R. Burlan, J. Tank, R. Fernández-Violante.
The elusive pathophysiology of neurally mediated syncope.
Circulation, (2000), 102 pp. 2898-2906
[28.]
B.P. Grub.
Neurocardiogenic syncope.
N Engl J Med, (2005), 352 pp. 1004-1010
[29.]
A. Moya, M. Brignole, C. Menozzi, R. García-Civera, S. Tognarini, L. Mont, International Study on Syncope of Uncertain Etiology (ISSUE) Investigators, et al.
Mechanism of syncope in patients with isolated and in patients with tilt-positive syncope.
Circulation, (2001), 104 pp. 1261-1267
[30.]
S.J. Connolly, R. Sheldon, R.S. Roberts, M. Gent, The North American Vasovagal Pacemaker Study (VPS).
A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope.
J Am Coll Cardiol, (1999), 33 pp. 16-20
[31.]
R. Sutton, M. Brignole, C. Menozzi, A. Raviele, P. Alboni, P. Giani, et al.
Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: Pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators.
Circulation, (2000), 102 pp. 294-299
[32.]
F. Ammirati, F. Colivichi, M. Santini, Syncope Diagnosis and Treatment Study Investigators.
Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: a multicenter randomized, controlled trial.
Circulation, (2001), 104 pp. 52-57
[33.]
S.J. Connolly, R. Sheldon, K.E. Thorpe, R.S. Roberts, K.A. Ellenbogen, B.L. Wilkoff, et al.
Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope.
JAMA, (2003), 283 pp. 2224-2229
[34.]
A. Raviele, F. Giada, C. Menozzi, G. Speca, S. Orazi, G. Gasparini, et al.
A randomized, double blind, placebo controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induce vasovagal syncope. The SYNPACE study.
Eur Heart J, (2004), 25 pp. 1741-1748
[35.]
E. Occhetta, M. Bortnik, R. Audoglio, C. Vassanelli, INVASY Study Investigators.
Closed loop stimulation in prevention of vasovagal syncope. Inotropy Controlled PACINE in Vasovagal Syncope (INVASY): a multicentre randomized, single blind, controlled study.
Europace, (2004), 6 pp. 538-547
[36.]
J. Healey, S.J. Connolly, C.A. Morillo.
The management of patients with carotid sinus syndrome: is pacing the answer?.
Clin Auton Res, (2004), 14 pp. 80-86
[37.]
R.A. Kenny, D.A. Richardson, N. Steen, R.S. Bexton, F.E. Shaw, J. Bond.
Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE).
J Am Coll Cardiol, (2001), 38 pp. 1491-1496
[38.]
G. Gregoratos, J. Abrams, A.E. Epstein, R.A. Freedman, D.L. Hayes, M.A. Hlatky, et al.
ACC/AHA/NASPE 2002 guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: summary article.
Circulation, (2002), 106 pp. 2145-2161
[39.]
Otras formas de síncope reflejo.
Síncope, MCR, pp. 209-219
[40.]
W. Omi, Y. Murata, T. Yaegashi, J. Inomata, M. Fujioka, S. Muramoto.
Swallow syncope, a case report and review of the literature.
Cardiology, (2006), 105 pp. 75-79
[41.]
A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, et al.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report.
JAMA, (2003), 289 pp. 2560-2572
[42.]
J. Hung, E.G. Whitford, R.W. Parsons, D.R. Hillman.
Association of sleep apnea with myocardial infarction in men.
Lancet, (1990), 336 pp. 261-264
[43.]
R. Wolk, V.K. Somers.
Cardiovascular consequences of obstructive sleep apnea.
Clin Chest Med, (2003), 24 pp. 195-205
[44.]
S.S. Stegman, J.M. Burroughs, R.W. Henthorn.
Asymptomatic bradyarrhythmias as a marker for sleep apnea: Appropiate recognition and treatment may reduce the need for pacemaker therapy.
Pace, (1996), 19 pp. 899-904
[45.]
A.S.M. Shamsuzzaman, B.J. Gersh, V.K. Somers.
Obstructive Sleep apnea. Implications for cardiac and vascular disease.
JAMA, (2003), 290 pp. 1906-1912
[46.]
L.J. Gula, A.D. Krahn, A.C. Skanes, R. Yee, G.J. Klein.
Clinical relevance of arrhythmias during sleep: Guidance for clinicians.
Heart, (2004), 90 pp. 347-352
[47.]
I. Fietza, J. Rottig, S. Quispe-Bravo, F. Riedel, J. Whitte, G. Baumann, et al.
Sleep apnea syndrome in patients with cardiac pacemaker.
Respiration, (2000), 67 pp. 268-271
[48.]
S. Garrigue, P. Bordier, P. Jais, C. Shah, M. Hocini, Ch. Raherison, et al.
Benefit of atrial pacing in sleep apnea syndrome.
N Engl J Med, (2002), 34 pp. 404-412
[49.]
L. Pepin, P. Defayé, C. Deschaux, Y. Poezevara, P. Levy.
No benefit of overdrive atrial pacing for treatment of obstructive sleep apnea syndrome (OSAS) [resumen].
Eur Respir J, (2003), 22 pp. S23
[50.]
R. García Calabozo, Martínez Ferrer, M.J. Sancho-Tello.
Temas de actualidad en estimulación cardiaca 2005.
Rev Esp Cardiol, (2006), 59 pp. 66-77
[51.]
E.N. Simantirakis, S. Schiza, S.I. Chrysostomakis, G.I. Chlouverakis, N.C. Klapsinos, N.M. Siafakas, et al.
Atrial overdrive pacing for the obstructive sleep apnea-hypopnea syndrome.
N Engl J Med, (2005), 353 pp. 2568-2577
[52.]
Ch. Scharf, Y.K. Cho, K.E. Bloch, C. Brunckhorst, F. Duru, K. Balaban, et al.
Diagnosis of sleep-related breathing disorders by visual analysis of transthoracic impedance signals in pacemakers.
Circulation, (2004), 110 pp. 2562-2567
[53.]
E.N. Simantirakis, P.E. Vardas.
Cardiac pacing in sleep apnoea: diagnosis and therapeutic implications.
Europace, (2006), 8 pp. 984-987
[54.]
E. Braunwald, C.T. Lambrew, S.D. Rockoff, J. Ross, A. Morrow.
Idiopathic Hypertrophic Subaortic Stenosis: A description of the disease based upon an analysis of 64 patients.
Circulation, (1964), 29-30 pp. 3-119
[55.]
B.J. Maron, R.O. Bonow, R.O. Cannon, M.B. Leon, S.E. Epstein.
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).
N Engl J Med, (1987), 316 pp. 780-789
[56.]
W.L. Henry, C.E. Clark, J.M. Griffith, S.E. Epstein.
Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (Idiopathic hypertrophic subaortic stenosis).
Am J Cardiol, (1975), 35 pp. 337-345
[57.]
A.M. Montijano, B. Bouzas, M. Penas, W.J. McKenna.
Estrategias terapéuticas en la miocardiopatía hipertrófica obstructiva sintomática.
Rev Esp Cardiol, (2001), 54 pp. 1311-1326
[58.]
B.J. Maron, R.O. Bonow, R.O. Cannon, M.B. Leon, S.E. Epstein.
Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2).
N Engl J Med, (1987), 316 pp. 844-852
[59.]
E.D. Wigle, H. Rakowski, B.P. Kimball, W.G. William.
Hypertrophic Cardiomyopathy. Clinical spectrum and treatment.
Circulation, (1995), 92 pp. 1680-1692
[60.]
R.E. Stenson, M.D. Flamm Jr, D.C. Harrison, E.W. Hancock.
Hypertrophic subaortic estenosis: clinical and hemodynamic effects of long-term propanolol therapy.
Am J Cardiol, (1973), 31 pp. 763-773
[61.]
A.G. Adelman, P.M. Shah, R. Grtamiack, E.D. Wigle.
Long-term propanolol therapy in muscular subaortic stenosis.
Br Heart J, (1970), 32 pp. 804-811
[62.]
D.R. Rosing, J.R. Condit, B.J. Maron, K.M. Kent, M.B. Leon, R.O. Bonow, et al.
Verapamil therapy: A new approach to pharmacologic treatment of hypertropic cardiomyopathy: III. Effects of longterm administration.
Am J Cardiol, (1981), 48 pp. 545-553
[63.]
P. Hanrath, D.G. Mathey, P. Kremer, F. Sonntag, W. Bleifeld.
Effect of verapamil on left ventricular isovolumic relaxation time and regional leaft ventricular filling in hypertrophic cardiomyopathy.
Am J Cardiol, (1980), 45 pp. 1258-1264
[64.]
C. Pollick.
Disopyramide in hypertrophic cardiomyopathy II. Noninvasive assessment after oral administration.
Am J Cardiol, (1988), 62 pp. 1252-1255
[65.]
W.J. McKenna, C.M. Oakley, D.M. Krikler, J.F. Goodwin.
Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
Br Heart J, (1985), 53 pp. 412-416
[66.]
W.P. Cleland.
The surgical management of obstructive cardiomyopathy.
J Cardiovasc Surg, (1963), 4 pp. 489-491
[67.]
A.G. Morrow, B.A. Reitz, S.E. Epstein, W.L. Henry, D.M. Conkle, S.B. Itscoitz, et al.
Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre- and post-operative assessment in 83 patients.
Circulation, (1975), 52 pp. 88-102
[68.]
D.A. Cooley, D.C. Wukasch, R.D. Leachman.
Mitral valve replacement for idiopathic hypertrophic subaortic stenosis: results in 27 patients.
J Cardiovasc Surg, (1976), 17 pp. 380-387
[69.]
R. Mohr, V. Hartzell, V. Schaff, K. Gordon, F.J. Puga, J.R. Pluth, et al.
The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy. Experience over 15 years.
J Thorac Cardiovasc Surg, (1989), 97 pp. 666-674
[70.]
A. Woo, W.G. Williams, R. Choi, E.D. Wigle, E. Rozenblyum, Fedwick., et al.
Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy.
Circulation, (2005), 111 pp. 2033-2041
[71.]
U. Sigwart.
Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.
Lancet, (1995), 346 pp. 211-214
[72.]
C. Knight, A.S. Kurbaan, H. Seggewiss, M. Henein, M. Gunning, D. Harrington, et al.
Non surgical septal reduction for hypertrophic obstructive cardiomyopathy.
Circulation, (1997), 95 pp. 2075-2081
[73.]
H. Seggewiss, L. Faber, U. Gleichmann.
Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
Thorac Cardiovasc Surg, (1999), 47 pp. 94-100
[74.]
F.H. Gietzen, C.J. Leuner, L. Obergassel, C. Strunk-Mueller, H. Kuhn.
Role of transcoronary ablation of septal Hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association Funcional clas III or IV, and outflow obstruction only under Provocable conditions.
Circulation, (2002), 106 pp. 454-459
[75.]
H. Seggewiss, U. Gleichmann, L. Faber, D. Fassbender, H.K. Schmidt, S. Strick.
Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up en 25 patients.
J Am Coll Cardiol, (1998), 31 pp. 259-264
[76.]
P. Hassenstein, H.H. Storch, W. Schmitz.
Erfahrungen mit der schrittmacher dauerbehandlung bei patienten mit obstruktiver kardiomyopathie.
Thoraxchirurgie, (1975), 23 pp. 496-498
[77.]
G. Duport, B. Valeix, J. Lefevre, J.C. Nebunu, J.M. Bouteau, M. Garcia-Duport, et al.
Interet de la stimulation ventriculaire droite permanente dans la cardiomyopathie obstructive.
Nouv Presse Med, (1978), 32 pp. 2868-2869
[78.]
K.M. McDonald, B. Maurer.
Permanent pacing as treatment for hypertrophic cardiomyopathy.
Am J Cardiol, (1991), 68 pp. 108-110
[79.]
L. Fananapazir, R.O. Cannon, D. Tripodi, J.A. Panza.
Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with sypmtoms refractory to verapamil and beta-adrenergic bloker therapy.
Circulation, (1992), 85 pp. 2149-2161
[80.]
X. Jeanrenaud, J. Goy, L. Kappenberger.
Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy.
Lancet, (1992), 339 pp. 1318-1323
[81.]
J. Tascón, A. Albarrán, M. P-Carasa, J. Andreu, J. Rodríguez, R. Coma, et al.
Tratamiento de la miocardiopatía hipertrófica obstructiva refractaria al tratamiento médico con estimulación DDD.
Rev Esp Cardiol, (1994), 47 pp. 294-302
[82.]
L. Fananapazir, N. Epstein, R. Curiel, J. Panza, D. Tripodi, D. McAreavey.
Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
Circulation, (1994), 90 pp. 2731-2742
[83.]
P. Blanch, A. Soto, P. Tornos, R. Bosch, A. Evangelista, J. Soler.
Marcapasos VVI en el tratamiento de la miocardiopatía hipertrófica obstructiva en fibrilación auricular.
Rev Esp Cardiol, (1993), 46 pp. 455-457
[84.]
J. Tascón, A. Albarrán, M. Alonso, J. Andreu, F. Lobera, P. Escribano, et al.
Respuesta hemodinámica inmediata a la estimulación bicameral en la miocardiopatía hipertrófica obstructiva severa.
Rev Esp Cardiol, (1996), 49 pp. 815-822
[85.]
J.C. Tascón, A. Albarrán, F. Hernández, M. Alonso, J. Andreu, R. Coma, et al.
Miocardiopatía hipertrófica obstructiva y estimulación secuencial auriculoventricular. Resultados agudos y seguimiento a largo plazo. Siete años de experiencia.
Rev Esp Cardiol, (2000), 53 pp. 1028-1039
[86.]
R.A. Nishimura, D.L. Hayes, D.M. Ilstrup, D.R. Holmes, J. Tajik.
Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute doppler echocardiographic and catheterization hemodynamic study.
J Am Coll Cardiol, (1996), 27 pp. 421-430
[87.]
S. Betocchi, M.A. Losi, F. Piscione, M. Boccalatte, L. Pace, P. Golino, et al.
Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function.
Am J.Cardiol, (1996), 77 pp. 498-502
[88.]
S. Betocchi, P.M. Elliott, C. Briguoti, M. Virdee, M.A. Losi, Y. Matsumura, et al.
Dual chamber pacing in hypertrophic cardiomyopathy: long-term effects on diastolic function.
Pacing Clin Electrophysiol, (2002), 25 pp. 1433-1440
[89.]
F. Meisel, T. Ruawolf, M. Burghart, L. Kapepenberger.
Pacemaker therapy of hypertrophic obstructive cardiomyopathy. PIC (Pacing in Cardiomyopathy) Study group.
Herz, (2000), 25 pp. 461-466
[90.]
L.J. Kappenberger, C. Linde, X. Jeanrenaud, C., M.cKenna. Daubert, E. Meisel, et al.
Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group.
Europace, (1999), 1 pp. 77-84
[91.]
B.J. Maron, R.A. Nishimura, W.J. McKenna, H. Rakowski, M.E. Josephson, R.S. Kieval, et al.
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory simptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY).
Circulation, (1999), 99 pp. 2927-2933
[92.]
R.A. Nishimura, J.M. Trusty, D.L. Hayes, D.M. Ilstrup, D.R. Larson, S.N. Hayes, et al.
Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind, crossover trial.
J Am Coll Cardiol, (1997), 29 pp. 435-441
[93.]
I. Topilski, J. Sherez, G. Keren, I. Copperman.
Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy > 50 year of age.
Am J Cardiol, (2006), 12 pp. 1769-1775
[94.]
M. Morí, T. Ichili, T. Kuga, A. Takeshita.
Evidence for anti-ischemic effect of dual-chamber pacing in patients with the obstructive form of hypertrophic cardiomyopathy.
Jpn Heart J, (2003), 44 pp. 587-592
[95.]
A. Megevand, J. Ingles, D.R. Richmond, C. Semsarian.
Long-term follow-up of patients with dual-chamber pacing.
Am J Cardiol, (2005), 95 pp. 991-993
[96.]
D. Pavin, C. de Place, H. Le Breton, C. Leclerq, D. Gras, F. Victor, et al.
Effects of permanent dual-chamber pacing on mitral regurgitation in hypertrophic obstructive cardiomyopathy.
Eur Heart J, (1999), 20 pp. 203-210
[97.]
T. Hozumi, T. Ito, M. Suwa, Y. Sakai, Y. Kitaura.
Effects of dualchamber pacing on regional myocardial deformation in patients with hypertrophic obstructive cardiomyopathy.
Circ J, (2006), 70 pp. 63-68
[98.]
R. Oter Rodríguez, J. De Juan Montiel, T. Roldán Pacual, A. Bardají Ruiz, E. Molinero de Miguel.
Guías de práctica clínica de la Sociedad Española de Cardiología en marcapasos.
Rev Esp Cardiol, (2000), 53 pp. 947-966
[99.]
J. Maron, W. McKenna, G. Danielson, L. Kappenberger, H. Kuhn, C. Seidman, et al.
American College of Cardiology/European Society of Cardiology clinical Exper Consensus Document on Hypertrophic Cardiomyopathy.
Eur Heart J, (2003), 24 pp. 1965-1991
[100.]
E.M. McNally, H. MacLeod.
Therapy insight: cardiovascular complications associated with muscular dystrophies.
Nat Clin Practice, (2005), 2 pp. 301-308
[101.]
J.L. Merino, R. Peinado.
Arrhythmias associated with neuromuscular disorders.
Cardiac Electrophysiol Rev, (1999), 3 pp. 224-226
[102.]
G. Pelargonio, A. Dello Russo, T. Sanna, G. De Martino, F. Bellocci.
Myotonic dystrophy and the Heart.
Heart, (2002), 88 pp. 665-670
[103.]
S.A. Nishioka, M.M. Filho, S. Marie, M. Zatz, R. Costa.
Myotonic dystrophy and Heart disease. Behavior of arrhythmic events and conduction disturbances.
Arq Bras Cardiol, (2005), 84 pp. 330-336
[104.]
A. Dello Russo, G. De Martino, L. Messano, G. Pelargonio, M. Pace, T. Sanna, et al.
Sudden cardiac death in Steinert muscular dystrophy: preliminary results of the Ramyd study.
Ital Heart J, (2004), 5 pp. S203-S211
[105.]
S. Mavrogeni, G.E. Tzelepis, G. Athanasopoulos, T.h. Maounis, M. Douskous, A. Papavasiliou, et al.
Cardiac and sternocleidomastoid muscle involvement in Duchenne muscular dystrophy.
An MRI Study Chest, (2005), 127 pp. 143-148
[106.]
T. Sanna, A. Dello Russo, D. Toniolo, M. Vytopil, G. Pelargonio, G. De Martino, et al.
Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutations.
Eur Heart J, (2003), 24 pp. 2227-2236
[107.]
A.E. Buckley, J. Dean, I.R. Mahy.
Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series.
Heart, (1999), 82 pp. 105-108
[108.]
G. Boriani, M. Gallina, L. Merlín, G. Bonne, D. Toniolo, S. Amati, et al.
Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy.
A long-term longitudinal study Stroke, (2003), 34 pp. 901-908
[109.]
K.E. Davis, M.D. Grounds.
Treating muscular dystrophy with stem cells.
Cell, (2006), 127 pp. 1304-1306
[110.]
G. Gregoratos, M.D. Cheitlin, A. Conill, A.E. Epstein, C. Fellows, T.B. Ferguson, et al.
ACC/AHA Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: executive sumary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on pacemaker implantation).
Circulation, (1998), 97 pp. 1325-1335
[111.]
M. Budeos, T. Back, H. Wieneke, R. Erbel, S. Sack.
Single-chamber versus dual-chamber implantable cardioverter defibrillators: Do we need physiologic pacing in the course?.
Indian Pacing Electrophysiol J, (2006), 6 pp. 153-162
[112.]
D. Iskos, G.J. Fahy, K.G. Lurie, S. Sakaguchi, J.M. Collins, J. Fetter, et al.
Physiologic cardiac pacing in patients with contemporary implantable cardioverter-defibrillators.
Am J Cardiol, (1998), 82 pp. 66-71
[113.]
S.L. Higgins, S.K. Williams, J.P. Pak, D.B. Meyer.
Indications for implantation of a dual-chamber pacemaker combined with an implantable cardioverter-defibrillator.
Am J Cardiol, (1998), 81 pp. 1360-1362
[114.]
C. Mezler, M. Böhm, H.J. Bondke, W. Combs, G. Baumann, H. Theres.
Chronotropic incompetence in patients with an implantable cardioverter defibrillator: prevalence and predicting factors.
Pace, (2005), 28 pp. 1025-1031
[115.]
P.J.M. Best, D.L. Hayes, M.S. Stanton.
The potential usage of dual chamber pacing in patients with implantable cardioverter defibrillators.
Pace, (1999), 22 pp. 79-85
[116.]
S.L. Higgins, S.K. Williams, J.P. Pak, D.B. Meyer.
Indications for implantation of a dual-chamber pacemaker combined with an implantable cardioverter-defibrillator.
Am J Cardiol, (1998), 81 pp. 1360-1362
[117.]
A. Proclemer, P. Della Bella, D. Facchin, L. Fattore, C. Carbucicchio, C. Tondo, et al.
Indications for dual-chamber cardioverter defibrillators at implant and a 1 year follow-up: a retrospective analysis in the single-chamber defibrillator era.
Europace, (2001), 3 pp. 132-135
[118.]
S. Higgins, J.P. Pak, J. Barone, S.K. Willians, F.M. Bollinger, S.L. Whiting, et al.
The first year experience with the dual chamber ICD.
Pace, (2000), 23 pp. 18-25
[119.]
W.D. Toff, A.J. Camm, J.D. Skehan, United Kingdom Pacing and Cardiovascular Events Trial Investigators.
Single-chamber versus dual-chamber pacing for high-grade atrioventricular block.
N Engl J Med, (2005), 353 pp. 145-155
[120.]
The DAVID Trial Investigators.
Dual-Chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
JAMA, (2004), 288 pp. 3115-3123
[121.]
A.D. Sharma, C. Rizo-Patron, A.P. Hallstrom, G.P. O’Neill, S. Rothabart, J.B. Martins, The DAVID investigators, et al.
Percent right ventricular pacing predicts outcomes in the DAVID trial.
Heart Rhythm, (2005), 2 pp. 830-834
[122.]
M.D. Smit, P. Van Dessel, W. Nieuwland, A. Wiesfeld, E.S. Tan, R.L. Anthonio, et al.
Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients.
Heart Rhythm, (2006), 3 pp. 1397-1403
[123.]
R. Sukhija, W.S. Aronow, C. Sorbera, P. Kakar, S.J. Peterson, W.H. Frishman, et al.
Left ventricular ejection fraction and prevalence of new left ventricular wall motion abnormality at long-term follow-up in patients with automatic implantable cardioverter-defibrillators treated with dual-chamber rate-responsive pacing at a rate of 70/minute versus backup ventricular pacing rate of 40/minute.
Am J Cardiol, (2005), 96 pp. 412-413
[124.]
C. Kolb, I. Deisenhofer, S. Schmieder, P. Barthel, B. Zrenner, M.R. Karch, et al.
Long-term follow-up of patients supplied with single-chamber or dual-chamber cardioverter defibrillators.
Pace, (2006), 29 pp. 946-952
[125.]
A.J. Moss, W. Zareba, J. Hall, H. Klein, D.J. Wilber, D.S. Cannom, et al.
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.
N Engl J Med, (2002), 366 pp. 877-883
[126.]
L.D. Berenbom, B.C. Weiford, J.L. Vacek, M.P. Emert, W.J. Hall, M.L. Andrews, For the MADIT-II Investigators, et al.
Differences in outcomes between patients treated with single versus dualchamber implantable cardioverter defibrillators: A substudy of the Multicenter Automatic Defibrillator Implantation Trial II.
Ann Noninvasive Electrocardiol, (2005), 10 pp. 429-435
[127.]
I. Goldenberg, A.J. Moss, J. Hall, S. McNitt, W. Zareba, M.L. Adews, For the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Investigators, et al.
Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators.
Circulation, (2006), 113 pp. 2810-2817
[128.]
J.S. Steinberg, A. Fischer, P. Wang, C. Schuger, J. Daubert, S. Mcnitt, et al.
The clinical implications of cumulative right ventricular pacing in the Multicenter Automatic Defibrillator Trial II.
J Cardiovasc Electrophysiol, (2005), 16 pp. 59-365
[129.]
J. Lee M, M.W. Dae, J.J. Langberg, J.C. Griffin, M.C. Chin, W.F. Finkbeiner, et al.
Effects of long-term right ventricular apical pacing on left ventricular perfusion, intervention, function and histology.
J Am Coll Cardiol, (1994), 24 pp. 225-232
[130.]
D. Baller, H.G. Wolpers, J. Zipfel, H.J. Bretschneider, G. Hellige.
Comparison of the effects of right atrial, right ventricular apex and atrioventricular sequential pacing on myocardial oxygen consumption and cardiac efficiency: a laboratory investigation.
Pace, (1988), 11 pp. 394-403
[131.]
A. Lubinski, T. Lewicka-Nowak, M. Kempa, B. Bielawska, R. Wilczek, G. Swiatecka.
Implantation and follow-up of ICD leads implanted in the right ventricular outflow tract.
Pace, (2000), 23 pp. 1996-1998
[132.]
M.C. Giudici, S.S. Barold, D.L. Paul, P.E. Schrumpf, K.J. Van Why, D.W. Orias.
Right ventricular outflow tract placement of defibrillation leads: five years experience.
Pace, (2004), 27 pp. 443-446
[133.]
R. Peinado, A. Arenal, F. Arribas, E. Torrecilla, M. Álvarez, J.M. Ormaetxe, et al.
Registro Español de Desfibrilador Automático Implantable. Primer Informe Oficial del Grupo de Trabajo de Desfibrilador Implantable de la Sociedad Española de Cardiología (años 2002-2004).
Rev Esp Cardiol, (2005), 58 pp. 1435-1449
[134.]
R. Peinado, E.G. Torrecilla, J. Ormaetxe, M. Álvarez.
Registro Español de DAI. II informe oficial del Grupo de Trabajo de Desfibrilador Implantable de la Sociedad Española de Cardiología (2005).
Rev Esp Cardiol, (2006), 59 pp. 1292-1302
[135.]
J.G.F. Cleland, J.C. Dauber, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, et al.
The effect of cardiac resynchronization on morbidity and mortality in heart failure.
N Engl J Med, (2005), 352 pp. 1539-1549
[136.]
M. Bristow, L.A. Saxo, J. Boehmer, S. Krueger, D.A. Kass, T. De Marco, et al.
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
N Engl J Med, (2004), 350 pp. 2140-2150
[137.]
Z. Goldberger, B. Elbel, C.A. McPherson, A.D. Paltiel, R. Lamper.
Cost advantage of dual-chamber versus single-chamber cardioverter-defibrillator implantation.
J Am Coll Cardiol, (2005), 46 pp. 850-857
[138.]
L. Mont.
Single-, dual-, or triple-chamber defibrillators: the simpler the better?.
Heart Rhythm, (2006), 3 pp. 1404-1405
[139.]
D. Bänsch, F. Steffgen, G. Grönefeld, C.h. Wolpert, D. Böcker, R.U. Mletzo, et al.
The 1 + 1 Trial. A Prospective trial of dual versus a single-chamber implantable defibrillator in patients with slow ventricular tachycardias.
Circulation, (2004), 110 pp. 1022-1029
[140.]
P.A. Friedman, R.L. McClelland, W.R. Banlet, H. Acosta, D. Kessler, T.M. Munger, et al.
Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis. The Detect Supraventricular Tachycardia Study.
Circulation, (2006), 113 pp. 2871-2876
[141.]
B. Olshansky, J.D. Day, S. Moore, L. Gering, M. Rosenbaum, M. Mc-Guire, et al.
Is dual-chamber programming inferior to singlechamber programming in an implantable cardioverter-defibrillator? Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) Study.
Circulation, (2007), 115 pp. 9-16
[142.]
M.O. Sweeney, J.B. Shea, V. Fox, S. Adler, L. Nelson, T.J. Mullen, et al.
Randomized pilot study of a new atrial-based minimal ventricular pacing mode in dual-chamber implantable cardioverter-defibrillators.
Heart Rhythm, (2004), 1 pp. 160-167
[143.]
G. Pioger, G. Leny, R. Nitzsche, A. Ripart.
AAIsafeR limits ventricular pacing in unselected patients.
Pace, (2007), 30 pp. S66-S70
Copyright ©
2007. Sociedad Española de Cardiología